hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Inclusion Criteria: * Standard risk GVHD patients with hematological malignancies older than 18 years; * High risk GVHD patients with hematological malignancies: haplotype hematopoietic stem cell transplantation patients, donor is female or more than 30 years old; * Well informed about this study and signed a consent form before the trial; * Left ventricular ejection fraction (LVEF) ≧ 50%, no evidence of pericardial effusion; * No evidence of lung infection by X-rays examination; * Eastern cooperative oncology group (ECOG) performance status of 0 or 1, Hematopoietic cell transplantation - specific comorbidity index (HCT-CI) of 0, 1, 2; * Normal liver and kidney function: Serum bilirubin≤35µmol/L, AST/ALT was less than 2 times the upper limit of normal value, and serum creatinine ≤130µmol/L Exclusion Criteria: * Reduce pretreatment dose or secondary transplantation; * Participate other clinical trials within 2 months before this study; * Female, 1) pregnant/nursing period, or 2) have a pregnancy plan during the study period, or 3) have fertility and cannot take effective contraception; * History of severe allergic disease or is allergic to one or more drugs; * Patients who are considered unsuitable for the study by the investigator.